Small molecule stimulators for use as adjuvants for antiviral vaccines

用作抗病毒疫苗佐剂的小分子刺激剂

• 批准号: 8751031
• 负责人: MICHAEL GALE
• 金额: $ 271.54万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2014-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8751031
• 关键词: Adjuvant; Antigens; Antiviral Agents; B-Lymphocytes; Communicable Diseases; Computer Simulation; Contracts; Genes; Goals; Human; Human Cell Line; Immune system; Immunologic Adjuvants; Immunologic Receptors; Immunotherapeutic agent; In Vitro; Lead; Libraries; Mus; Pathway interactions; Preclinical Testing; RNA Viruses; Reporter Genes; Research Personnel; Small Interfering RNA; Study models; T-Lymphocyte; Techniques; Testing; Vaccines; base; cell mediated immune response; high throughput screening; in vivo; macrophage; monocyte; prevent; programs; promoter; receptor; receptor function; small molecule

The goals of the Innate Immune Receptors and Adjuvant Discovery program are to discover, characterize, and support preclinical testing of new adjuvant candidates based upon triggering of the human innate immune system. Adjuvants are defined as molecules that act via innate immune receptors to activate beneficial innate and/or adaptive (T and B cell-mediated) immune responses. Using high throughput screening techniques, investigators will screen compound libraries to identify potential adjuvant products that may be developed as components of antigen specific vaccines against infectious disease, or may serve as stand-alone agents that transiently prevent or treat infectious disease.

先天免疫受体和佐剂发现计划的目标是发现、表征和支持基于人类先天免疫系统触发的新佐剂候选物的临床前测试。佐剂被定义为通过先天免疫受体发挥作用以激活有益的先天和/或适应性（T 和 B 细胞介导的）免疫反应的分子。使用高通量筛选技术，研究人员将筛选化合物库，以确定潜在的佐剂产品，这些产品可以开发为针对传染病的抗原特异性疫苗的成分，或者可以作为暂时预防或治疗传染病的独立制剂。